Actively Recruiting
Randomized Study Evaluating Safety and Pharmacokinetics of GIGA-2339 IV Doses in Adults with Chronic Hepatitis B Virus Infection
Led by GigaGen, Inc. · Updated on 2026-09-25
48
Participants Needed
20
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and tolerability of single and multiple intravenous doses of GIGA-2339 in adults with chronic Hepatitis B Virus HBV infection. This Phase 1 randomized, double-blind, placebo-controlled study aims to understand how GIGA-2339 behaves in the body and monitor any side effects in participants with stable HBV infection. Participants will receive either a single ascending dose or multiple ascending doses of GIGA-2339 or placebo through intravenous infusion. In Part 1, they get a single infusion on Day 1, and in Part 2, they receive multiple infusions every 4 weeks at doses determined from Part 1. The study compares these treatments to placebo to evaluate safety and pharmacokinetics. During the study, participants undergo regular blood tests to measure drug levels and monitor safety up to Day 105 for the single dose and Day 245 for multiple doses. Researchers record any adverse events and serious side effects. The study lasts until November 2028, with ongoing assessments of participants responses and tolerability throughout the dosing and follow-up periods.
CONDITIONS
Brief Title
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of GIGA-2339 in Participants With Chronic Hepatitis B Virus Infection
Research Team
E
Enrikas Vainorius, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here